ArticleCancer discovery2019
Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents.
Abstract read
In one paragraph
Article in Cancer discovery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models.Blood advances · 2020Trial
- Metabolic vulnerabilities and therapeutic opportunities in diffuse large B-cell lymphoma.Oncogenesis · 2026Review
- Patient-derived ovarian cancer models demonstrate the influence of tumor-associated macrophages on therapeutic response.Oncoimmunology · 2025Article
- Transcriptomics of Various Diseases Reveals the Core Role of Immune System Pathways in Retinal Damage Repair and Nerve Regeneration.Molecular neurobiology · 2025Article
- The battle within: cell death by phagocytosis in cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- Advancements in Hydrogel-Based Therapies for Ovarian Cancer: A Review.Cell biochemistry and biophysics · 2025Review
- Lymphoma cell-driven IL-16 is expressed in activated B-cell-like diffuse large B-cell lymphomas and regulates the pro-tumor microenvironment.Haematologica · 2025Article
- Macrophages are activated toward phagocytic lymphoma cell clearance by pentose phosphate pathway inhibition.Cell reports. Medicine · 2024Article
- Adverse clinical outcomes and immunosuppressive microenvironment of RHO-GTPase activation pattern in hepatocellular carcinoma.Journal of translational medicine · 2024Article
- Macrophages in tumor cell migration and metastasis.Frontiers in immunology · 2024Review
- Pro-inflammatory macrophages suppress HIV replication in humanized mice andFrontiers in immunology · 2024Article
- Empowering macrophages: the cancer fighters within the tumour microenvironment in mantle cell lymphoma.Frontiers in immunology · 2024Review
- Antibody-mediated phagocytosis in cancer immunotherapy.Immunological reviews · 2023Review
- Advances in single-cell RNA sequencing and its applications in cancer research.Journal of hematology & oncology · 2023Review
- The Role of Macrophage Populations in Skeletal Muscle Insulin Sensitivity: Current Understanding and Implications.International journal of molecular sciences · 2023Review
- Review
- Melittin-Carrying Nanoparticle Suppress T Cell-Driven Immunity in a Murine Allergic Dermatitis Model.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Modeling the crosstalk between malignant B cells and their microenvironment in B-cell lymphomas: challenges and opportunities.Frontiers in immunology · 2023Review
- Coadministration with bendamustine restores the antitumor activity of obinutuzumab in obinutuzumab-resistant tumors.International journal of hematology · 2022Article
- Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy.Science advances · 2022Article
Corrections and comments
- Commented on by
Authors and funding
24 authors.
Chen LossosDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Yunpeng LiuBroad Institute of MIT and Harvard University, Cambridge, Massachusetts.
Kellie E KolbBroad Institute of MIT and Harvard University, Cambridge, Massachusetts.
Amanda L ChristieDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Alexandria Van ScoykDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Sanjay M PrakadanBroad Institute of MIT and Harvard University, Cambridge, Massachusetts.
Kay ShigemoriDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-9682-4164
Kristen E StevensonDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Sara MorrowDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Olivia D PlanaDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Cameron FraserJohn B. Little Center for Radiation Sciences, Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Kristen L JonesDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Huiyun LiuDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Christian P PallaschDepartment of Internal Medicine, University Hospital of Cologne, Cologne, Germany.ORCID 0000-0001-5675-6905
Rebecca ModisteLurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Quang-De NguyenLurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Jeffrey W CraigDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0003-1295-3258
Elizabeth A MorganDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-5880-9337
Francisco VegaDivision of Hematopathology, Department of Pathology and Laboratory Medicine, University of Miami/Sylvester Comprehensive Cancer Center, Miami, Florida.ORCID 0000-0001-5956-452X
Jon C AsterDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Kristopher A SarosiekJohn B. Little Center for Radiation Sciences, Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Alex K ShalekBroad Institute of MIT and Harvard University, Cambridge, Massachusetts.ORCID 0000-0001-5670-8778
Michael T HemannBroad Institute of MIT and Harvard University, Cambridge, Massachusetts.
David M WeinstockDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. davidm_weinstock@dfci.harvard.edu.ORCID 0000-0002-8724-3907
Funding
VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI MATTHEW G. VANDER HEIDEN · 1985 to 2026
$93.9MRole of Negative Costimulation in Regulation of AutoimmunityP01AI039671 · NIAID · YALE UNIVERSITY · PI David A. Hafler · 1996 to 2026
$51.7MSystems investigation of vaccine responses in B cell depleted autoimmune patientsU19AI089992 · NIAID · YALE UNIVERSITY · PI David A. Hafler, RUTH R MONTGOMERY · 2010 to 2026
$50.4MMedical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0MCenter for Cell CircuitsRM1HG006193 · NHGRI · BROAD INSTITUTE, INC. · PI BLAINEY, PAUL CLARK, HACOHEN, NIR · 2016 to 2020
$14.9MQuantitative and functional characterization of therapeutic resistance in cancerU54CA217377 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LAUFFENBURGER, DOUGLAS A · 2017 to 2021
$10.2MA systems biology approach to fingerprint HIV immune defense in Elite ControllersR01HL134539 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI YU, XU · 2016 to 2019
$3.3MDevelopmental regulation of apoptosis as a modifiable driver of radiotherapy-induced neurocognitive impairment in pediatric patientsR37CA248565 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Kristopher Andrew Sarosiek · 2020 to 2026
$2.6M"Bottom - Up" Profiling of Interacting Cellular SystemsDP2GM119419 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI SHALEK, ALEX K · 2015 to 2015
$2.3MAn integrated multiplexed genomic assay for low input clinical samples1U24AI118672 · NIAID · BROAD INSTITUTE, INC. · PI SHALEK, ALEX K · 2015 to 2019
$2.0MClinical implementation of single cell tumor transcriptome analysisR33CA202820 · NCI · BROAD INSTITUTE, INC. · PI GOLUB, TODD R., JOHNSON, BRUCE E. · 2016 to 2018
$1.3MRegulation of Apoptotic Priming and Competence in Healthy and Cancerous CellsR00CA188679 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI SAROSIEK, KRISTOPHER ANDREW · 2017 to 2019
$747kNCI NIH HHS P30 CA014051NCI NIH HHS R00 CA188679NCI NIH HHS R33 CA202820NCI NIH HHS R37 CA248565NCI NIH HHS U54 CA217377NHGRI NIH HHS RM1 HG006193NHLBI NIH HHS R01 HL134539NIAID NIH HHS P01 AI039671NIAID NIH HHS U19 AI089992NIAID NIH HHS U24 AI118672NIGMS NIH HHS DP2 GM119419NIGMS NIH HHS T32 GM007753
Abstract
The extraordinary activity of high-dose cyclophosphamide against some high-grade lymphomas was described nearly 60 years ago. Here we address mechanisms that mediate cyclophosphamide activity in bona fide human double-hit lymphoma. We show that antibody resistance within the bone marrow (BM) is not present upon early engraftment but develops during lymphoma progression. This resistance required a high tumor:macrophage ratio, was recapitulated in spleen by partial macrophage depletion, and was overcome by multiple, high-dose alkylating agents. Cyclophosphamide induced endoplasmic reticulum (ER) stress in BM-resident lymphoma cells
Indexed as
AlemtuzumabAlkylating AgentsAnimalsAntibodies, MonoclonalBone MarrowCell Line, TumorCyclophosphamideDose-Response Relationship, DrugEndoplasmic Reticulum StressHumansLymphoma, B-CellMacrophagesMiceMice, Inbred NODMice, SCIDRandom AllocationAlemtuzumabAlkylating AgentsAntibodies, MonoclonalCyclophosphamide
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.